The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment

Pan Zhang(China Pharmaceutical University), Meirong Huo(China Pharmaceutical University), Xuxin Chu(China Pharmaceutical University), Xinyuan Zhou(Academy of Medical Sciences), Yongwei Gu(Fudan University Shanghai Cancer Center), Nan Liu(Nanfang Hospital), Fangnan Lv(China Pharmaceutical University), Jianping Zhou(Xinjiang University), Lifang Yin(Jilin University), Jiyong Liu(Shanghai Medical College of Fudan University), Chao Qin(Ludong University)
Biomaterials
April 12, 2022
Cited by 68


Related Papers